Therapy with thrombolytic agents in coronary artery disease

Current Opinion in Cardiology

Volumn 13, Issue 4, 1998, Pages 267-273

  Hanna, George P ^a   Smalling, Richard W ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; FIBRINOLYTIC AGENT; HEPARIN; LANOTEPLASE; PROUROKINASE; RETEPLASE; STAPHYLOKINASE; STREPTOKINASE; STREPTOKINASE DERIVATIVE; TISSUE PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR DERIVATIVE; TNK PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE;

ACUTE HEART INFARCTION; ANAPHYLAXIS; ARTERY THROMBOSIS; ASYSTOLE; BACKACHE; BLOOD CLOTTING; CARDIOGENIC SHOCK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DRUG EFFICACY; FEVER; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LUNG EMBOLISM; MORTALITY; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; REVIEW; RIGOR; STROKE; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031852618     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199807000-00007     Document Type: Review

References (39)

1. Bulkeley BH: The Heart, ed 6. New York: McGraw Hill; 1986.
2. Lie JT: Coronary thrombosis and acute myocardial infarction. Cardiovasc Clin 1988, 18:23-40.
3. Misinski M: Pathophysiology of acute myocardial infarction: a rationale for thrombolytic therapy Heart Lung 1988, 17:743-750
4. White JG: Platelet structural physiology: the ultrastructure of adhesion, secretion, and aggregation in arterial thrombosis. Cardiovasc Clin 1987, 18:13-33.
5. Collen D: On the regulation of and control of fibrinolysis. Thromb Haemostat 1980, 43:77-89.
6. Collen D: Molecular mechanisms and clinical applications of thrombolysis. Les Cahiers de la fondation Louis Jeantet de Medicine 1986, 1:41-54.
7. DeWood MA, Spores J, Notchke R, Mouser LT, Burroghs R, Golden MS, Lang HT: Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980, 303:897-902.
8. Reimer KA, Jennings RB: The "wave front phenomenon" of myocardial ischemic death: transmural progression of necrosis within the framework of ischemic bed size, (myocardium at risk) and collateral flow. Lab Invest 1979, 40:633-644,
9. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB: The "wave front phenomenon" of ischemic cell death: I. Myocardial size vs duration of coronary occlusion in dogs. Circulation 1977, 56:786-793.
10. Gruppo Itlaiano Per lo Studio Streptochinasi Nell'infarto Miocardico (GISSI): Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986, 1:397-384
11. ISIS2 (Second International Study of Infarct Survival) collaborative group: Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17187 case of suspected acute myocardial infarction Lancet 1988, 8607:349-360.
12. Sharma GVRK, Cella G, Parisi AF, Sashara AA: Thrombolytic therapy. N Engl J Med 1982, 306:1268-1276.
13. Mathey DG, Schofer J, Sheehan FH: Intravenous urokinase in acute myocardial infarction. J Am Coll Cardiol 1988, 55:878-882.
14. Neuhaus KL for the GAUS study group: Thrombolysis in acute myocardial infarction: Results of the German-Activator Urokinase Study (GAUS). Eur Heart J 1987, 8:49-52.
15. The PRIMI trial study group: Randomised double blind trial of recombinant prourokinase against streptokinase in acute myocardial infarction. Lancet 1989, 2:863-868.
16. TIMI-I. A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987, 76:142-154.
17. GISSI-II: A factorial randomised trial of alteplase versus streptokinase and heparin versus no hepann among 12,490 patients with acute myocardial infarction Lancet 1990, 336:65-71.
18. ISIS-3: In-hospital mortality and clinical: course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without hepann. Lancet 1990, 336:71-75.
19. The GUSTO Investigators: An international randomised trial comparing four thrombolytic strategies for AMI. N Engl J Med 1993, 329:673-682.
20. The GUSTO Angiographic Investigators: Effects of tissue plasminogen activator, streptokinase, or both on coronary artery-patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993, 329:1615-1622.
21. Martin U, Kohler J, Sponer G, Strein K: Pharmacokinetics of the novel recombinant plasminogen activator BM 06.0222 in rats, dogs, and non-human primates. Fibrinolysis 1992, 6:39-43.
22. Martin U, Sponer G, Strein K: Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.0222 in a canine model of coronary artery thrombosis. J Am Coll Cardiol 1992, 19:433-440.
23. Tebbe U, von ESÏssen R, Smolarz A, Limbourg P. Rox J, Rüstige J, Vogt A, Wagner J, Meyer-Sabelleck W, Neuhaus KL: Open, noncontrolled dose finding study with a novel recombinant plasminogen activator (BM 06.0222) given as a double bolus in patients with acute myocardial infarction. Am J Cardiol 1993, 72:518-524
24. Smallmg RW, Bode C, Kalbflesch J, Sen S, Feldman R, Mann D, Limbourg P, Forycki F, Habib G, Feldman R, Hohnloser S. Seals A, and the RAPID investigators: More rapid, complete and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995, 91:2725-2732.
25. Smalling RW, Bode C, Kalbfleisch J, Sen S, Feldman R, Mann D, Limbourg P, Odenheimer DJ, Meyer-Sabellek W, and the RAPID investigators: Improvement of global and regional LV-function by the bolus administration of recombinant plasminogen activator (r-PA) in acute myocardial infarction: a comparison with standard dose alteplase [abstract]. Circulation 1994, 90(suppl 1):1-562.
26. International Joint Efficacy Comparison of Thrombolytics: Randomised, double blind comparison ol reteplase double bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence Lancet 1995, 346:320-336.
27. Cannon CP, McCabe CH, Gibson CM, Ghali M, Seqeira RF, McKendall GR, Breed J, Modi NB, Fox NL, Tracy RP, Love TW, Braunwald E: TNK-tissue plasminogen activator in acute myocardial infarction: results on the Thrombolysis in Myocardial Infarction (TIMI) 10A dose ranging trial. Circulation 1997, 95:351-356
28. Preliminary data of IN-TIME-1. TIMI 10a and ASSENT I: Presented at the 70th Scientific Session of the American Heart Association, November 1997.
29. Kohnert U, Rudolph R, Verheijen JH, Weening-Verhoef EJ, Stern A, Optiz U, Martin U, Lill H, Prinz H, Lechner M: biochemical properties of the Kringle 2 and protease domains are maintained in the refolded I-PA deletion variant BM 06.022. Protein Eng 1992, 5(1):93-100.
30. Hu CK, Kohnert U, Sturzebecher J, Fischer S, Llinas M: Complexation of the tissue plasminogen activator protease with benzamidine-inhibitors: interference by the Kringle 2 module. Biochem 1996, 35(101:3270-3276.
31. Schlott B, Hartmann M, Guhrs KH, Birch-Hirshfeld E, Pohl HD, Vanderschueren S, Van de Werf F, Michoel A, Collen D, Behnke D: High yield production and purification of recombinant staphylokinase for thronbolytic therapy. Biotechnology 1993, 12:185-189
32. Vandershueren S, Barrios L, Kerdsichai P, Van den Huevel, Hermans L, Vrolix M, de Man P, Benit E, Muyldermans L, Collen D, Van der Werf F: A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 1995, 92:2044-2049.
33. Gardell SJ, Duong LT, Diel RE. Isolation, characterization, and cDNA cloning of a vampire bat salivary plasminogen activator. J Biol Chem 1989, 264:17947-17952.
34. Bringmannn P, Gruber D, Liese A, et al.: Structural features mediating fibrin selectivity of fibrin selectivity of vampire bat plasminogen activators. J Biol Chem 1995, 270:25596-25603.
35. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators: A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997, 337:1118-1123.
36. Van Belle E, Leblanche JM, Bauters C, Renaud N, McFadden EP, Bertrand ME: Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: natural history and the effect of thrombolysis. Circulation 1998, 97:26-33.
37. Smalling RW, Anderson HV: Pathophysiological insight into the possible optimal therapies for acute myocardial infarction and unstable angina. Circulation 1998, 97:10-11.
38. Benedict CR, Mueller S, Anderson HV, Willerson JT: Thrombolytic therapy: a state of the art. Hosp Pract 1992, 1:16-72.
39. Smalling RW, Hanna GP: American Journal of Cardiology Continued Education Series, 1997.